SCHEMBL22638697

SCHEMBL22638697

CCOC(=O)c1ccc(S(N)(=O)=O)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
LMNA P02545 2/20 0.50
PPARG P37231 1/20 0.50
NCOA2 Q15596 1/20 0.50
NCOA1 Q15788 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
NCOA3 Q9Y6Q9 1/20 0.50
CA2 P00918 9/20 0.49
STS P08842 1/20 0.45
CA1 P00915 3/20 0.44
ERN1 O75460 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CA12 O43570 2/20 0.42
CA9 Q16790 2/20 0.42
CA7 P43166 1/20 0.42
CA14 Q9ULX7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14592924 0.85 HDAC3 (0.54) HDAC3HDAC4HDAC1HDAC6LMNA
SCHEMBL5323270 0.84 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC6LMNA
SCHEMBL2006698 0.81 NPSR1 (0.74) LMNAPPARGNCOA2NCOA1NPSR1
SCHEMBL22638687 0.81 LMNA (0.51) HDAC3HDAC4HDAC1HDAC6LMNA
SCHEMBL22638709 0.81 HDAC4 (0.50) HDAC3HDAC4HDAC1HDAC6LMNA
SCHEMBL7018973 0.80 HDAC3 (0.73) HDAC3HDAC4HDAC1HDAC6LMNA
SCHEMBL30444689 0.79 LMNA (0.53) HDAC3HDAC4HDAC1HDAC6LMNA
SCHEMBL5023778 0.76 HDAC3 (0.58) HDAC3HDAC4HDAC1HDAC6LMNA
SCHEMBL21844839 0.75 CA2 (0.49) LMNAPPARGNCOA2NCOA1NPSR1
SCHEMBL2659566 0.75 HDAC3 (0.62) HDAC3HDAC4HDAC1HDAC6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114206335-B KCNT1 inhibitors and methods of use 普拉克西斯精密药物股份有限公司 2025-03-11 CN disclosed
EP-4446314-A2 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2024-10-16 EP disclosed
EP-3962479-B1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2024-07-24 EP disclosed
US-20220411392-A1 Amide Derivative And Preparation Method Therefore And Use Thereof In Medicine CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) 2022-12-29 US disclosed
US-20220280476-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2022-09-08 US disclosed
US-20220280476-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2022-09-08 US disclosed
CN-114206335-A KCNT1 inhibitors and methods of use 普拉克西斯精密药物股份有限公司 2022-03-18 CN disclosed
EP-3962479-A1 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2022-03-09 EP disclosed
WO-2021093820-A1 AMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE 成都百裕制药股份有限公司 2021-05-20 WO disclosed
WO-2020227097-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2020-11-12 WO disclosed
WO-2020227097-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220280476-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 HDAC3 1223/4885HDAC4 1064/4885HDAC1 1680/4885
US-20220411392-A1 Amide Derivative And Preparation Method Therefore And Use Thereof In Medicine NLRP3, NLRP1, PYCARD HDAC3 163/4885HDAC4 1324/4885HDAC1 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.